Výsledky vyhledávání - "Hepatitis B

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

Autor: Harry L A Janssen, Jinlin Hou, Tarik Asselah, Henry L Y Chan, Fabien Zoulim, Yasuhito Tanaka, Ewa Janczewska, Ronald G Nahass, Stefan Bourgeois, Maria Buti, Pietro Lampertico, Oliver Lenz, Thierry Verbinnen, Joris Vandenbossche, Willem Talloen, Ronald Kalmeijer, Maria Beumont, Michael Biermer, Umesh Shukla

Publikováno v: Gut. BMJ Publishing Group
Scientia

ObjectiveWe present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier:NCT03361956).Design232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppress

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f702b8cc4a17edfe62562c85466ffa3f
https://doi.org/10.1136/gutjnl-2022-328041

Zobrazit plný text záznamu

Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

Publikováno v: Scientia

COVID-19; Hepatitis B; Tenofovir COVID-19; Hepatitis B; Tenofovir COVID-19; Hepatitis B; Tenofovir Background and Aims HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than tho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::932ba24b491187cb9df755c7b3aa7bd2
https://doi.org/10.1007/s10620-022-07817-w

Zobrazit plný text záznamu

A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three European countries, 2019

Autor: Anthony Nardone, Lina Nerlander, Erika Duffell, Marta Valenciano, Maria Buti, Cristina Marcos-Fosch, Tatjana Nemeth-Blažić, Odette Popovici, Adriana Vince, Petruta Violeta Filip, Tajana Filipec, Mirjana Lana Kosanović Ličina, Boris Luksic, Diana Nonković, Corina Silvia Pop, Fabiana Radu, Irina Teodorescu, Adriana Violeta Topan

Publikováno v: Scientia

Background The World Health Organization European Action Plan 2020 targets for the elimination of viral hepatitis are that > 75% of eligible individuals with chronic hepatitis B (HBV) or hepatitis C (HCV) are treated, of whom > 90% achieve viral supp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe1f344f67eb9c791494b7d8b676c66
https://hdl.handle.net/11351/9162

Zobrazit plný text záznamu

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels

Publikováno v: Journal of Hepatology, 76(5), 1042-1050. Elsevier
Scientia

Background & Aims: Nucleo(s)tide analogue (NUC) withdrawal may result in HBsAg clearance in a subset of patients. However, predictors of HBsAg loss after NUC withdrawal remain ill-defined. Methods: We studied predictors of HBsAg loss in a global coho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37c0d7cb4797db9a98e45e120981aaf6
https://pure.eur.nl/en/publications/eebbff8c-6a0f-448f-8386-4b40ac00d785

Zobrazit plný text záznamu

Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up

Autor: Maria Francesca Cortese, Mar Riveiro-Barciela, David Tabernero, Francisco Rodriguez-Algarra, Adriana Palom, Sara Sopena, Ariadna Rando-Segura, Luisa Roade, Alison Kuchta, Roser Ferrer-Costa, Josep Quer, Beatriz Pacin, Marta Vila, Rosario Casillas, Selene Garcia-Garcia, Rafael Esteban, Tomás Pumarola, Maria Buti, Francisco Rodriguez-Frias

Publikováno v: Scientia

Antiviral treatment; Biomonitoring Tratamiento antiviral; Biomonitorización Tractament antiviral; Biomonitorització The measurement and interpretation of HBV DNA and RNA levels in HBV infected patients treated with antiviral therapy supports the ob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ab43e9449a9f3e4b6fb50ee3053d748
https://pubmed.ncbi.nlm.nih.gov/35377229

Zobrazit plný text záznamu

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B

Autor: Maria Buti, Rafael Esteban, Luisa Roade, Mar Riveiro-Barciela

Publikováno v: Therapeutic Advances in Infectious Disease, Vol 8 (2021)
Therapeutic Advances in Infectious Disease
Scientia

ETV; VHB; Hepatitis viral ETV; VHB; Viral hepatitis ETV; VHB; Hepatitis viral Nucleos(t)ide analogues with high barrier to resistance are regarded as the principal therapeutic option for chronic hepatitis B (CHB). Treatment with entecavir (ETV), teno

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::624d01f8e0adfb1acf0b660a4ecbbf2a
https://doi.org/10.1177/2049936120985954

Zobrazit plný text záznamu

Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues

Autor: Broquetas, Teresa, Garcia-Retortillo, Montserrat, Hernandez, Juan José, Puigvehí, Marc, Cañete Hidalgo, Nuria, Coll, Susanna, Cabrero, Beatriz, Giménez, Maria Dolors, Solà, Ricard, Carrión, José A., Universitat Autònoma de Barcelona

Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
PLoS ONE, Vol 12, Iss 11, p e0188303 (2017)
PLoS ONE

Background: HBeAg-negative chronic hepatitis B patients require long-term nucleos(t)ide analogues (NAs) because loss of surface antigen (HBsAg) is unusual. Low quantitative HBsAg (qHBsAg) levels can identify patients with higher probability of serocl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53475663d9f5ad837205652792b4ef2e
https://ddd.uab.cat/record/249579

Zobrazit plný text záznamu

Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study

Autor: Mariano Gómez Rubio, José Manuel Zozaya, Javier E. López, P. Castillo, Rosa Maria Morillas, Maria Luisa Manzano, Luis Morano, Manuel J. Rodriguez, Martín Prieto, E. Suárez, Jose Luis Calleja, Rafael Esteban, M. Yébenes, Leticia Martín, Montserrat García-Retortillo, María Laura Gutiérrez, Miguel Angel Simón, Maria Buti

Publikováno v: PLoS ONE, Vol 12, Iss 9, p e0184550 (2017)
PLoS ONE
Plos One
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Background Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdc9cee217f1aa0b8892f3935236308b
https://doi.org/10.1371/journal.pone.0184550

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání